Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Adherence to Antidepressants in Korean Elderly Patients with Major Depressive Disorder

주요우울장애 노인 환자의 항우울제 복약이행도 연구

  • Kyeong Ju Lee (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University) ;
  • Yu Jeung Lee (Department of Clinical Pharmacy, College of Pharmacy, Kangwon National University)
  • Received : 2023.01.07
  • Accepted : 2023.02.16
  • Published : 2023.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Adherence is an important component in the treatment of various diseases, and poor adherence to antidepressants in patients with major depressive disorder is common. Non-adherence can be more prevalent in elderly patients with multiple morbidity and polypharmacy, resulting in negative treatment outcomes. The purpose of this study was to analyze adherence to antidepressants in Korean elderly patients with major depressive disorder. Method: A retrospective study was conducted using the Korean National Health Insurance claims database, and the subjects of this study were patients aged 65 or older who received at least one prescription of antidepressant monotherapy for the treatment of major depressive disorder between January 1, 2020 and June 30, 2020. Adherence was measured using the proportion of days covered at 6 months after the initial antidepressant prescription date. Logistic regression analysis was used to identify factors associated with adherence. Results: A total of 416,766 patients were finally included in the study. Over half of patients were non-adherent (52.67%) to antidepressants. According to the multivariate logistic regression analysis, national health insurance or medical aid, taking selective serotonin reuptake inhibitors or selective norepinephrine reuptake inhibitors, and having comorbidities were significantly associated with greater rates of adherence in the study subjects. The highest adherence rate was observed in patients taking vortioxetine. Conclusion: There was a considerable rate of non-adherence in Korean elderly patients with major depressive disorder. Health care professionals should try to improve adherence in elderly patients with major depressive disorder.

Keywords

Acknowledgement

이 논문은 2022년도 강원대학교 대학회계의 지원을 받아 수행한 연구임.

References

  1. Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 2015;76(2):155-62. https://doi.org/10.4088/JCP.14m09298
  2. Compton WM, Conway KP, Stinson FS, et al. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991-1992 and 2001-2002. Am J Psychiatry 2006;163(12):2141-7. https://doi.org/10.1176/ajp.2006.163.12.2141
  3. Association AP. Practice guidelines for the treatment of patients with major depressive disorder, 3rd edition. Available from https:// psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/ guidelines/mdd.pdf. Accessed December 20, 2022.
  4. Seo JS, Bahk WM, Woo YS, et al. Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary. Clin Psychopharmacol Neurosci 2021;19(4):751-72. https://doi.org/10.9758/cpn.2021.19.4.751
  5. Prukkanone B, Vos T, Burgess P, et al. Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand. BMC Psychiatry 2010;10:64.
  6. Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry 2009;9:38.
  7. Keyloun KR, Hansen RN, Hepp Z, et al. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs 2017;31(5):421-32. https://doi.org/10.1007/s40263-017-0417-0
  8. Mauskopf JA, Simon GE, Kalsekar A, et al. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety 2009;26(1):83-97. https://doi.org/10.1002/da.20505
  9. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55(12):1128-32. https://doi.org/10.1001/archpsyc.55.12.1128
  10. Renom-Guiteras A, Meyer G, Thurmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol 2015;71(7):861-75. https://doi.org/10.1007/s00228-015-1860-9
  11. Olsson J, Bergman A, Carlsten A, et al. Quality of drug prescribing in elderly people in nursing homes and special care units for dementia: a cross-sectional computerized pharmacy register analysis. Clin Drug Investig 2010;30(5):289-300. https://doi.org/10.2165/11534320-000000000-00000
  12. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11(1):44-7. https://doi.org/10.1111/j.1524-4733.2007.00213.x
  13. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006;40(7-8):1280-88. https://doi.org/10.1345/aph.1H018
  14. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care 2009;15(7):457-64.
  15. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15(8):565-74. https://doi.org/10.1002/pds.1230
  16. Malo S, Aguilar-Palacio I, Feja C, et al. Different approaches to the assessment of adherence and persistence with cardiovasculardisease preventive medications. Curr Med Res Opin 2017;33(7): 1329-36. https://doi.org/10.1080/03007995.2017.1321534
  17. Forbes CA, Deshpande S, Sorio-Vilela F, et al. A systematic literature review comparing methods for the measurement of patient persistence and adherence. Curr Med Res Opin 2018;34(9):1613-25. https://doi.org/10.1080/03007995.2018.1477747
  18. Baumgartner PC, Haynes RB, Hersberger KE, et al. A Systematic Review of Medication Adherence Thresholds Dependent of Clinical Outcomes. Front Pharmacol 2018;9:1290.
  19. Liu X, Tepper PG, Able SL. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder. Int Clin Psychopharmacol 2011;26(3):173-80. https://doi.org/10.1097/YIC.0b013e328343ba1e
  20. Mantarro S, Capogrosso-Sansone A, Tuccori M, et al. Allopurinol adherence among patients with gout: an Italian general practice database study. Int J Clin Pract 2015;69(7):757-65. https://doi.org/10.1111/ijcp.12604
  21. Chang TE, Park S, Yang Q, et al. Association between long-term adherence to class-I recommended medications and risk for potentially preventable heart failure hospitalizations among younger adults. PLoS One 2019;14(9):e0222868.
  22. Hwang JE, Song I, Lee EK, et al. Prevalence and predictors of tricyclic antidepressant use among elderly Koreans in primary-care and specialty clinics. Int J Clin Pharmacol Ther 2018;56(5):224-30. https://doi.org/10.5414/CP203157
  23. Sultana J, Spina E, Trifiro G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opin Drug Metab Toxicol 2015;11(6):883-92. https://doi.org/10.1517/17425255.2015.1021684
  24. Hung CI. Factors predicting adherence to antidepressant treatment. Curr Opin Psychiatry 2014;27(5):344-9. https://doi.org/10.1097/YCO.0000000000000086
  25. Jeon-Slaughter H. Economic factors in of patients' nonadherence to antidepressant treatment. Soc Psychiatry Psychiatr Epidemiol 2012;47(12):1985-98. https://doi.org/10.1007/s00127-012-0497-6
  26. Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14(8):1291-304. https://doi.org/10.1517/14740338.2015.1046836
  27. De Diego-Adelino J, Crespo JM, Mora F, et al. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf 2022;21(5):673-90. https://doi.org/10.1080/14740338.2022.2019705
  28. Ta JT, Sullivan SD, Tung A, et al. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder. J Manag Care Spec Pharm 2021;27(2):223-39.
  29. Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. J Affect Disord 2018;229:421-8. https://doi.org/10.1016/j.jad.2017.12.056
  30. Thase ME, Danchenko N, Brignone M, et al. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. Eur Neuropsychopharmacol 2017;27(8):773-81.  https://doi.org/10.1016/j.euroneuro.2017.05.009